Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

4D Molecular Therapeutics (FDMT) Return on Capital Employed: 2021-2025

Historic Return on Capital Employed for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to -0.56%.

  • 4D Molecular Therapeutics' Return on Capital Employed fell 27.00% to -0.56% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.56%, marking a year-over-year decrease of 27.00%. This contributed to the annual value of -0.45% for FY2024, which is 5.00% down from last year.
  • 4D Molecular Therapeutics' Return on Capital Employed amounted to -0.56% in Q3 2025, which was down 16.83% from -0.48% recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Return on Capital Employed high stood at -0.21% for Q2 2021, and its period low was -0.56% during Q3 2025.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.34% (2023), whereas its average is -0.37%.
  • In the last 5 years, 4D Molecular Therapeutics' Return on Capital Employed climbed by 21bps in 2024 and then dropped by 27bps in 2025.
  • 4D Molecular Therapeutics' Return on Capital Employed (Quarterly) stood at -0.25% in 2021, then declined by 18bps to -0.43% in 2022, then grew by 9bps to -0.34% in 2023, then remained steady at -0.34% in 2024, then declined by 27bps to -0.56% in 2025.
  • Its last three reported values are -0.56% in Q3 2025, -0.48% for Q2 2025, and -0.40% during Q1 2025.